Dasatinib (SprycelÒ, Bristol‑Myers Squibb Pharma), also a second generation TKI, inhibits the tyrosine kinase activity of the BCR-ABL protein. It was developed to be effective in imatinib-resistant CML, and for patients with side effects to imatinib.

It is approved for:

  • Newly‑diagnosed patients in any of the phases of CML
  • Patients with resistance or intolerance to previous treatments